RAPT Therapeutics

RAPT Therapeutics is a clinical-stage biopharmaceutical company based in South San Francisco, United States. It is driven by a mission to treat inflammatory and immunologic diseases, developing therapeutics that target key drivers of the immune system. Its pipeline focuses on the CCR4 pathway and other key pathways, and includes Ozureprubart, a long-acting anti-IgE antibody for food allergy. GSK has entered an agreement to acquire RAPT Therapeutics.

RAPT Therapeutics is a clinical-stage biopharmaceutical company based in South San Francisco, United States. It is driven by a mission to treat inflammatory and immunologic diseases, with science focused on developing therapeutics that target key drivers of the immune system. Its pipeline is focused on the clinically important CCR4 and other key pathways, and includes Ozureprubart, a long-acting anti-IgE antibody for food allergy. GSK has entered an agreement to acquire RAPT Therapeutics.

Clinical-stage biopharmaceutical company focused on inflammatory and immunologic diseases.

• Ozureprubart

  A long-acting anti-IgE antibody for food allergy.

• 2019-12-04

  RAPT and Hanmi announce FLX475 Asia license and collaboration[2]RAPT与Hanmi宣布FLX475亚洲授权与合作biospectrumasia.com

  RAPT Therapeutics and Hanmi Pharmaceutical announced a license and collaboration agreement for FLX475 in Asia. Hanmi received an exclusive license to develop and commercialize the cancer treatment in South Korea and China, including Taiwan and Hong Kong, and will conduct a Phase 2 trial in Korea and China.

1. 1Homepage - RAPT Therapeuticsrapt.com
2. 2RAPT与Hanmi宣布FLX475亚洲授权与合作biospectrumasia.com